Search
THE MOST TALKED ABOUT ADVANCES AT THE 2023 AAD MEETING
The latest in skin health and cosmetic dermatology.
VIDEO: GLADSKIN, LEVEL EX PARTNER FOR EDUCATIONAL DERMATOLOGY VIDEO GAME
NEW ORLEANS - Gladskin and Level Ex have partnered to create a medical video game designed to teach dermatologists how Gladskin's eczema...
VIDEO: VISUALDX TOOL OFFERS EQUITABLE DERMATOLOGY DIAGNOSTICS
NEW ORLEANS - In this Healio video exclusive from the American Academy of Dermatology Annual Meeting, Art Papier, MD, founder and CEO...
VIDEO: JOHNSON & JOHNSON PRESENTS ‘WIDE BREADTH AND DEPTH' OF RESEARCH AT AAD 2023
NEW ORLEANS - Johnson & Johnson presented data in multiple areas at the American Academy of Dermatology Annual Meeting. In this Healio...
NOVEL SINGLE-USE PATCH SHOWS PROMISE FOR AXILLARY HYPERHIDROSIS
The patch is currently undergoing review by the US Food and Drug Administration. MDedge News
DELGOCITINIB SAFE, EFFICACIOUS IN CHRONIC HAND ECZEMA
NEW ORLEANS - Phase 3 trial results found delgocitinib cream to significantly improve patient and clinician-reported outcomes of hand...
DERMATOLOGY RISKS ARE LIKELY DIFFERENT FOR JAK INHIBITORS
Black box warnings for JAK inhibitors arise from rheumatoid arthritis studies, leading one expert to question the risk-benefit relevance...
TARGETED ALKALI THERMOLYSIS PATCH LESSENS SWEATING, DISEASE SEVERITY IN HYPERHIDROSIS
NEW ORLEANS -The targeted alkali thermolysis patch was safe and effective in the treatment of excessive axillary sweating or primary...
‘EARLY INTERVENTION' KEY TO IMPROVE SKIN CANCER OUTCOMES IN WOMEN WITH SKIN OF COLOR
NEW ORLEANS - Clinicians should be mindful of unique skin cancer presentations and risks in women with skin of color, according to...
BRAF, MEK INHIBITORS ‘SAVING LIVES' AS HISTIOCYTIC DISORDER TREATMENT
NEW ORLEANS - BRAF and MEK inhibitors may show promise as a treatment option for children and adults with histiocytic disorders, according...
PATIENTS WITH PIGMENTARY MOSAICISM EXHIBIT LOW RATES OF NEUROLOGICAL ABNORMALITIES
Neurological abnormalities were not highly associated with pigmentary mosaicism, with only 14.8% of patients with the disorder exhibiting...
DERMTECH ADDS APPROXIMATELY 1.9 MILLION COVERED LIVES FOR THE FOUNDATIONAL ASSAY OF ITS DERMTECH MELANOMA TEST
LA JOLLA, Calif.--DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced...
INTERNATIONAL WOMEN'S DAY 2023: SALICYLIC ACID OR GLYCOLIC ACID? KNOW WHICH IS BETTER TO IMPROVE YOUR SKINCARE ROUTINE
The topical use of both Glycolic Acid and Salicylic Acid helps resolve various dermatological concerns due to their medicinal effectiveness.
DERMTECH REPORTS FOURTH-QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS; COMPANY ANNOUNCES CEO TRANSITION PLAN
LA JOLLA, Calif.--DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported...
DUPILUMAB LEVELS HIGH IN TEARS OF PATIENTS WITH MODERATE TO SEVERE OCULAR SURFACE DISEASE
Patients with atopic dermatitis and moderate to severe ocular surface disease who were treated with dupilumab had higher levels of...
LONG-TERM SAFETY, EFFICACY OF CLASCOTERONE CREAM SHOWN IN ACNE TREATMENT
MIAMI BEACH, Fla. - Clascoterone cream 1% demonstrated long-term efficacy and a favorable safety profile in patients aged older than...
ADULTS TAKING DUPILUMAB FOR ATOPIC DERMATITIS ALSO SEE IMPROVEMENTS IN MILD ASTHMA
Adults who were taking dupilumab for their atopic dermatitis also experienced significant improvements in their mild asthma, primarily...
ADOLESCENTS BENEFIT FROM GENDER-AFFIRMING CARE
MIAMI BEACH, Fla. - Dermatologists are often on the forefront of care for many gender-diverse adolescents and can benefit these patients...
ACNE MEDICATION ADHERENCE REMAINS A CHALLENGE FOR TEENS
MIAMI BEACH, Fla. - One of the main challenges of treating adolescent patients with acne is adherence, creating a need for practitioners...
AS ACTINIC KERATOSES CASES INCREASE, SO DO POTENTIAL TREATMENT OPTIONS
MIAMI BEACH, Fla. - Emerging treatments for actinic keratoses promise a brighter future for patients as phase 2 trials show high efficacy...